CRI Scientific Advisory Council

Donate

Composed of leaders in immunology and immuno-oncology, the Scientific Advisory Council guides the Cancer Research Institute's research programs, deciding which promising scientific and medical research proposals will receive CRI funding and support.

Director

James P. Allison, Ph.D.

The University of Texas MD Anderson Cancer Center

Associate Directors

Glenn Dranoff, M.D.

Novartis Institutes for Biomedical Research

Carl F. Nathan, M.D.

Weill Cornell Medicine

Kunle Odunsi, M.D., Ph.D.

The University of Chicago

Ellen Puré, Ph.D.

University of Pennsylvania School of Veterinary Medicine

Robert D. Schreiber, Ph.D.

Washington University School of Medicine

E. John Wherry, Ph.D.

University of Pennsylvania School of Medicine

Jedd D. Wolchok, M.D., Ph.D.

Weill Cornell Medicine

Members

Frederick W. Alt, Ph.D.

Boston Children’s Hospital & Harvard Medical School

Richard Axel, M.D.

Columbia University

Nina Bhardwaj, M.D., Ph.D.

Icahn School of Medicine at Mount Sinai

Harvey Cantor, M.D.

Dana-Farber Cancer Institute & Harvard Medical School

Jonathan Cebon, Ph.D., FRACP

Olivia Newton-John Cancer Research Institute

Zhijian Chen, Ph.D.

University of Texas Southwestern Medical Center

Max D. Cooper, M.D.

Emory University

Lisa M. Coussens, Ph.D.

Oregon Health and Science University

Peter Cresswell, Ph.D.

Yale University

Jason G. Cyster, Ph.D.

University of California, San Francisco

Mark M. Davis, Ph.D.

Stanford University

Charles G. Drake, M.D., Ph.D.

NewYork-Presbyterian / Columbia University Medical Center

Michael L. Dustin, Ph.D.

University of Oxford

Kate A. Fitzgerald, Ph.D, MRIA

University of Massachusetts Medical School

Richard A. Flavell, Ph.D., FRS

Yale University

Thomas Gajewski, M.D., Ph.D.

The University of Chicago

Laurie H. Glimcher, M.D.

Dana-Farber Cancer Institute

Philip D. Greenberg, M.D.

Fred Hutchinson Cancer Research Center & University of Washington

Nir Hacohen, Ph.D.

Broad Institute of MIT and Harvard

James R. Heath, Ph.D.

Institute for Systems Biology

F. Stephen Hodi, M.D.

Dana-Farber Cancer Institute

Axel Hoos, M.D., Ph.D.

Scorpion Therapeutics

Patrick Hwu, M.D.

Moffitt Cancer Center

Darrell J. Irvine, Ph.D.

Massachusetts Institute of Technology

Dirk Jaeger, M.D.

National Center for Tumor Diseases Heidelberg

Elizabeth M. Jaffee, M.D.

Johns Hopkins University School of Medicine

Carl H. June, M.D.

University of Pennsylvania School of Medicine

Susan M. Kaech, Ph.D.

Salk Institute for Biological Studies

Michael Kalos, Ph.D.

Next Pillar Consulting, LLC

Michael Karin, Ph.D.

University of California, San Diego

John M. Kirkwood, M.D.

University of Pittsburgh School of Medicine

Alexander Knuth, M.D.

Hamad Medical Corporation

Lewis L. Lanier, Ph.D.

University of California, San Francisco

Christina S. Leslie, Ph.D.

Memorial Sloan Kettering Cancer Center

Hyam I. Levitsky, M.D.

Century Therapeutics

Ming O. Li, Ph.D.

Memorial Sloan Kettering Cancer Center

Dan R. Littman, M.D., Ph.D.

New York University Medical Center

Nils Lonberg, Ph.D.

Canaan Partners

J. Christopher Love, Ph.D.

Massachusetts Institute of Technology

Tak W. Mak, Ph.D., D.Sc., FRSC

University Health Network

Philippa C. Marrack, Ph.D.

National Jewish Health & University of Colorado

Cornelis J.M. Melief, M.D., Ph.D.

Leiden University Medical Center

Ira Mellman, Ph.D.

Genentech, Inc.

Miriam Merad, M.D., Ph.D.

Icahn School of Medicine at Mount Sinai

Malcolm A.S. Moore, D.Phil.

Memorial Sloan Kettering Cancer Center

Lee Nadler, M.D.

Harvard Medical School & Dana-Farber Cancer Institute

Drew M. Pardoll, M.D., Ph.D.

Johns Hopkins University School of Medicine

Klaus Rajewsky, M.D.

Max Delbrueck Center for Molecular Medicine

Gwendalyn J. Randolph, Ph.D.

Washington University in St. Louis

Anjana Rao, Ph.D.

La Jolla Institute for Immunology

Antoni Ribas, M.D., Ph.D.

University of California, Los Angeles Comprehensive Cancer Center

Stanley R. Riddell, M.D.

Fred Hutchinson Cancer Research Center & University of Washington

Alexander Rudensky, Ph.D.

Memorial Sloan Kettering Cancer Center

Bijan Safai, M.D., D.Sc.

New York Medical College

Shimon Sakaguchi, M.D., Ph.D.

Osaka University

Lawrence E. Samelson, M.D.

National Cancer Institute, NIH

Hans Schreiber, M.D., Ph.D.

The University of Chicago

Ton N. Schumacher, Ph.D.

The Netherlands Cancer Institute & Leiden University Medical Center

Padmanee Sharma, M.D., Ph.D.

The University of Texas MD Anderson Cancer Center

Craig L. Slingluff Jr., M.D.

University of Virginia Health System

Pramod K. Srivastava, M.D., Ph.D.

University of Connecticut School of Medicine

Susumu Tonegawa, Ph.D.

Massachusetts Institute of Technology

Giorgio Trinchieri, M.D.

National Cancer Institute, NIH

Emil R. Unanue, M.D.

Washington University School of Medicine

Marcel van den Brink, M.D., Ph.D.

Memorial Sloan Kettering Cancer Center

Ulrich H. von Andrian, M.D., Ph.D.

Harvard Medical School

Robert H. Vonderheide, M.D., D.Phil.

University of Pennsylvania

Jennifer Wargo, M.D.

The University of Texas MD Anderson Cancer Center

Hao Wu, Ph.D.

Boston Children's Hospital & Harvard Medical School

Kai W. Wucherpfennig, M.D., Ph.D.

Dana-Farber Cancer Institute

Cassian Yee, M.D.

The University of Texas MD Anderson Cancer Center

Rolf M. Zinkernagel, M.D., Ph.D.

University of Zurich

Let's spread the word about Immunotherapy! Click to share this page with your community.

Copy Link

*Immunotherapy results may vary from patient to patient.

Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111

800-992-2623 212-832-9376 Staff Directory

Stay Connected with CRI

Recent Blog Posts

A recent diabetes-related discovery by CRI Lloyd J. Old STAR Dr. Andrea Schietinger has promising implications for cancer immunotherapy

Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.

Top